Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from
dividing so they stop growing or die. Oblimersen may increase the effectiveness of
gemcitabine by making cancer cells more sensitive to the drug. This phase I trial is studying
the side effects and best dose of oblimersen and gemcitabine in treating patients with
metastatic or unresectable solid tumors or lymphoma